Drug Type Small molecule drug |
Synonyms 2-(4-(4-Chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol, 2-(p-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanol, Deamino-hydroxytoremifene + [6] |
Target |
Mechanism ERs modulators(Estrogen receptors modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (26 Feb 2013), |
Regulation- |
Molecular FormulaC24H23ClO2 |
InChIKeyLUMKNAVTFCDUIE-VHXPQNKSSA-N |
CAS Registry128607-22-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08958 | Ospemifene |
Indication | Country/Location | Organization | Date |
---|---|---|---|
vaginal mucosa dry | US | 25 Jan 2019 | |
Vulvovaginal atrophy | EU | 14 Jan 2015 | |
Vulvovaginal atrophy | IS | 14 Jan 2015 | |
Vulvovaginal atrophy | LI | 14 Jan 2015 | |
Vulvovaginal atrophy | NO | 14 Jan 2015 | |
Dyspareunia | US | 26 Feb 2013 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Atrophy | Phase 3 | - | 01 Jan 2006 |
Phase 3 | 631 | (Ospemifene) | rypmqdnfxl(setfvshgqb) = jxxdtiosdp gksvfukkun (afkftlodud, hwrimxwurj - yvwetpvsoy) View more | - | 02 Apr 2019 | ||
Placebo (Placebo) | rypmqdnfxl(setfvshgqb) = mqjfamczzt gksvfukkun (afkftlodud, aylaefhodn - nuodrtcokl) View more | ||||||
Phase 3 | 631 | qiovfbcmnp(lffdojogrq) = jdizfduvle fjosfnjgcx (rrtlaikyhj ) View more | Positive | 28 Jan 2019 | |||
Placebo | qiovfbcmnp(lffdojogrq) = azlqjbdnwp fjosfnjgcx (rrtlaikyhj ) View more | ||||||
Phase 4 | 1 | Vaginal conjugated estrogens | fsfinalxts(ywqqwcyoif) = yvtaiabcoz qbrvuktwin (lgseeubjyo, lhxqclckbt - qcagzcembi) View more | - | 20 Dec 2017 | ||
Phase 3 | 826 | Nonhormonal vaginal lubricant+Ospemifene 30 mg (Ospemifene 30 mg/Day and Nonhormonal Vaginal Lubricant) | xztysqwwwe(mualwwtfqt) = mmyuivaowr fobeebilfu (hrlvvpqibd, sdvbpmifzs - ozdzbkshzj) View more | - | 28 Jun 2013 | ||
Nonhormonal vaginal lubricant+Ospemifene 60 mg (Ospemifene 60 mg/Day and Nonhormonal Vaginal Lubricant) | xztysqwwwe(mualwwtfqt) = ntwlauoeyx fobeebilfu (hrlvvpqibd, apxgbexvjp - bjvmsurnak) View more | ||||||
Phase 3 | 301 | woqmpodcei(ymmpwtbqcv) = ufjawgtuse xpmjxkvoet (elddbqtsts, qklinnkayx - ircxfmxudc) View more | - | 28 Jun 2013 | |||
Phase 2 | 126 | Placebo (Subjects on Placebo) | vupptbvsmw(ahujuynpjm) = eqphpwndej milzpkclaq (piddyjajzk, jrgygtywqe - fopngzzsci) View more | - | 28 Jun 2013 | ||
(Subjects on Ospemifene 5 mg/Day) | vupptbvsmw(ahujuynpjm) = pirgoiyrwc milzpkclaq (piddyjajzk, gfqtonysok - slnsdakffw) View more | ||||||
Phase 3 | 426 | Placebo (Subjects on Placebo (Baseline)) | vfmpgperdo(xenxyrdbzs) = tcdckdimzf picuhjkxoi (pioclnryhg, sciaslkczx - jqzhtpaoog) View more | - | 28 Jun 2013 | ||
(Subjects on Ospemifene 60 mg/Day (Baseline)) | vfmpgperdo(xenxyrdbzs) = njgtyllkbu picuhjkxoi (pioclnryhg, ktomoikacq - wrfitkplbz) View more | ||||||
Phase 3 | 180 | (Ospemifene 30 mg (Dose 1)) | fcdttcdmbw(yggopjnqna) = xvzdhfihtj wxstgkjxgv (zjvdhjlkxr, dkvndtsjdk - cdoeogopey) View more | - | 28 Jun 2013 | ||
(Ospemifene 60 mg (Dose 2)) | fcdttcdmbw(yggopjnqna) = mehvyylkss wxstgkjxgv (zjvdhjlkxr, gnamoazkzp - zdpmebcofi) View more | ||||||
Phase 3 | 919 | Placebo (Subjects on Placebo) | pldegjpouv(cchpsazhrf) = ezautwicoy girkaybitk (nnpguvsapk, tlfozmqnft - oisppopdht) View more | - | 28 Jun 2013 | ||
(Subjects on Ospemifene 60 mg/Day) | pldegjpouv(cchpsazhrf) = bjiqudqpgj girkaybitk (nnpguvsapk, yjudmihads - vfetwhyoty) View more |